Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of dalfampridine on mobility in daily life in multiple sclerosis
2014-003498-41Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalfampridine in multiple sclerosis (MS), sponsored by Medical University of Vienna. Primary endpoint: Change in gait mobility. Started Aug 2015; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-003498-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003498-41.